Bluejay Diagnostics (NASDAQ:BJDX) vs. Inspira Technologies OXY B.H.N. (NASDAQ:IINN) Critical Survey

Bluejay Diagnostics (NASDAQ:BJDX) and Inspira Technologies OXY B.H.N. (NASDAQ:IINN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and price targets for Bluejay Diagnostics and Inspira Technologies OXY B.H.N., as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	0	0	0	0	0.00
Inspira Technologies OXY B.H.N.	0	0	1	0	3.00

Inspira Technologies OXY B.H.N. has a consensus target price of $2.00, indicating a potential upside of 65.29%. Given Inspira Technologies OXY B.H.N.’s stronger consensus rating and higher possible upside, analysts clearly believe Inspira Technologies OXY B.H.N. is more favorable than Bluejay Diagnostics.

Volatility & Risk

Bluejay Diagnostics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Inspira Technologies OXY B.H.N. has a beta of 2.28, meaning that its stock price is 128% more volatile than the S&P 500.

Earnings and Valuation

This table compares Bluejay Diagnostics and Inspira Technologies OXY B.H.N.”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	$250,000.00	9.36	-$7.72 million	($125.15)	-0.01
Inspira Technologies OXY B.H.N.	N/A	N/A	-$11.05 million	N/A	N/A

Bluejay Diagnostics has higher revenue and earnings than Inspira Technologies OXY B.H.N..

Profitability

This table compares Bluejay Diagnostics and Inspira Technologies OXY B.H.N.’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-362.07%	-299.10%
Inspira Technologies OXY B.H.N.	N/A	N/A	N/A

Insider & Institutional Ownership

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 12.7% of Inspira Technologies OXY B.H.N. shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 29.4% of Inspira Technologies OXY B.H.N. shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Inspira Technologies OXY B.H.N. beats Bluejay Diagnostics on 7 of the 10 factors compared between the two stocks.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.

About Inspira Technologies OXY B.H.N.

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.